Viage Therapeutics

Viage Therapeutics is a biotechnology company developing therapies that stimulate the central nervous system (CNS) through the gut-brain axis. Viage's clinical candidate, DGX-001, is an orally administered drug that targets the AVPR1A receptor in the gut. The mechanism of action of DGX-001 involves modulating the vagus nerve through specific receptor interactions on enteroendocrine cells within the intestines, thereby regulating brain cell activity.